VCEL
Vericel Corporation · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | +1 | 11.40K | $456,516 | +1 | n/a |
| Q2 2026 | 99 | +1 | 33.10M | $1.47B | +8 | −7 |
| Q1 2026 | 101 | +5 | 32.45M | $1.04B | +9 | −4 |
| Q4 2025 | 96 | +4 | 34.49M | $1.24B | +4 | n/a |
| Q3 2025 | 17 | +1 | 19.50M | $613.54M | +2 | −1 |
| Q2 2025 | 13 | -2 | 17.99M | $765.41M | n/a | −2 |
| Q1 2025 | 12 | 0 | 5.43M | $242.28M | +1 | −1 |
| Q4 2024 | 12 | 0 | 5.41M | $297.03M | +1 | −1 |
| Q3 2024 | 11 | 0 | 2.16M | $91.36M | n/a | n/a |
| Q2 2024 | 11 | n/a | 1.70M | $78.09M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wealth Enhancement Advisory… | 11.39K | +5.9% | $456,240 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | TD Waterhouse Canada Inc. | 7 | New | $276 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| TD Waterhouse Canada Inc. | $276 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 278 holders, 55.09M shares, $1.70B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 7.00K sh · $311,710
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology